# Study of HS-10241 in Combination With Almonertinib in Patients With Locally Advanced or Metastatic NSCLC

> **NCT05430386** · PHASE1 · UNKNOWN · sponsor: **Jiangsu Hansoh Pharmaceutical Co., Ltd.** · enrollment: 174 (estimated)

## Conditions studied

- Non Small Cell Lung Cancer

## Interventions

- **DRUG:** HS-10241

## Key facts

- **NCT ID:** NCT05430386
- **Lead sponsor:** Jiangsu Hansoh Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-01-05
- **Primary completion:** 2023-12-31
- **Final completion:** 2023-12-31
- **Target enrollment:** 174 (ESTIMATED)
- **Last updated:** 2023-02-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05430386

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05430386, "Study of HS-10241 in Combination With Almonertinib in Patients With Locally Advanced or Metastatic NSCLC". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT05430386. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*